公开(公告)号：US07115606B2

公开(公告)日：2006-10-03

申请号：US10863770

申请日：2004-06-07

申请人： Steven B. Landau ,  Cheryl L. Miller ,  Matthew O. Fraser

发明人： Steven B. Landau ,  Cheryl L. Miller ,  Matthew O. Fraser

IPC分类号： A61K31/496

CPC分类号： A61K31/519 ,  A61K31/00 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

摘要翻译： 本发明涉及一种治疗需要治疗的受试者的下尿路疾病的至少一种症状的方法，其中所述症状选自尿频，尿急，尿急迫性尿失禁，夜尿和遗尿。 该方法包括向需要治疗的受试者施用治疗有效量的具有5-HT 3受体拮抗剂活性和NorAdrenaline再摄取抑制剂（NARI）活性的化合物。 本发明还涉及在需要治疗的受试者中治疗下尿路障碍的至少一种症状的方法，其中所述症状选自尿频，尿急，尿急迫性尿失禁，夜尿和遗尿， 包括向所述受试者共同施用第一量的5-HT 3拮抗剂和第二量的NARI，其中第一和第二量一起包含治疗有效量或各自以治疗有效的量存在 量。

公开(公告)号：US06846823B2

公开(公告)日：2005-01-25

申请号：US10817332

申请日：2004-04-02

申请人： Steven B. Landau ,  Cheryl L. Miller ,  Matthew O. Fraser

发明人： Steven B. Landau ,  Cheryl L. Miller ,  Matthew O. Fraser

IPC分类号： A01N43/54 ,  A61K31/00 ,  A61K31/135 ,  A61K31/519 ,  A61K31/535 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06

CPC分类号： A61K31/519 ,  A61K31/00 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

公开(公告)号：US07094786B2

公开(公告)日：2006-08-22

申请号：US10846979

申请日：2004-05-14

申请人： Steven B. Landau ,  Cheryl L. Miller ,  Karl B. Thor

发明人： Steven B. Landau ,  Cheryl L. Miller ,  Karl B. Thor

IPC分类号： A61K31/496

CPC分类号： A61K31/135 ,  A61K31/519 ,  A61K31/535 ,  A61K31/551 ,  A61K41/00 ,  A61K45/06 ,  A61K2300/00

摘要： Methods are disclosed for the treatment of nausea and vomiting in a patient suffering therefrom comprising administering 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine.

摘要翻译： 公开了用于治疗患有恶心和呕吐的患者的方法，包括给予4-（2-氟苯基）-6-甲基-2-（1-哌嗪基）噻吩并[2,3-D]嘧啶。

公开(公告)号：US20090131471A1

公开(公告)日：2009-05-21

申请号：US12156787

申请日：2008-06-04

申请人： Suhail Nurbhai ,  Steven B. Landau

发明人： Suhail Nurbhai ,  Steven B. Landau

IPC分类号： A61K31/439 ,  A61P1/00

CPC分类号： A61K31/439

摘要： The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount is from about one to about three daily doses of the compound and the dose is from about 0.2 mg to about 0.5 mg.

摘要翻译： 本发明涉及治疗需要治疗的人类受试者中的GERD的方法。 所述方法包括向所述受试者口服施用有效量的结构式I的噻吩并[3,2-b]吡啶化合物或其药学上可接受的盐或N-氧化物衍生物，其中有效量为约1至约3 化合物的日剂量和剂量为约0.2mg至约0.5mg。

公开(公告)号：US20180140630A1

公开(公告)日：2018-05-24

申请号：US15820821

申请日：2017-11-22

申请人： M. Michael Wolfe ,  Steven B. Landau ,  Abhijeet Waghray ,  Nisheet Waghray

发明人： M. Michael Wolfe ,  Steven B. Landau ,  Abhijeet Waghray ,  Nisheet Waghray

IPC分类号： A61K33/08 ,  A61K9/00 ,  A61P1/04 ,  A61K31/734 ,  A61K31/426 ,  A61K31/4164 ,  A61K31/341

CPC分类号： A61K33/08 ,  A61K9/0053 ,  A61K31/341 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/734 ,  A61P1/04

摘要： A combination of an antacid, alginate, and a histamine H2-receptor antagonist, and methods of using the same for providing fast and lasting relief of symptoms of episodic heartburn are provided.

公开(公告)号：US20100247584A1

公开(公告)日：2010-09-30

申请号：US12752702

申请日：2010-04-01

申请人： Suhail Nurbhai ,  Steven B. Landau

发明人： Suhail Nurbhai ,  Steven B. Landau

IPC分类号： A61K9/00 ,  A61K31/439 ,  A61P1/04

CPC分类号： A61K31/439

摘要： The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount is from about one to about three daily doses of the compound and the dose is from about 0.2 mg to about 0.5 mg.

摘要翻译： 本发明涉及治疗需要治疗的人类受试者中的GERD的方法。 所述方法包括向所述受试者口服施用有效量的结构式I的噻吩并[3,2-b]吡啶化合物或其药学上可接受的盐或N-氧化物衍生物，其中有效量为约1至约3 化合物的日剂量和剂量为约0.2mg至约0.5mg。

公开(公告)号：US20080275080A1

公开(公告)日：2008-11-06

申请号：US12082419

申请日：2008-04-11

申请人： Matthew Oliver Fraser ,  Karl Bruce Thor ,  Edward C. Burgard ,  Lee R. Brettman ,  Steven B. Landau ,  Daniel J. Ricca

发明人： Matthew Oliver Fraser ,  Karl Bruce Thor ,  Edward C. Burgard ,  Lee R. Brettman ,  Steven B. Landau ,  Daniel J. Ricca

IPC分类号： A61K31/46 ,  A61K31/195 ,  A61K31/216 ,  A61K31/135 ,  A61K31/445

CPC分类号： A61K45/06 ,  A61K31/195 ,  A61K31/197 ,  A61K31/216 ,  A61K2300/00

摘要： A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

摘要翻译： 提供了一种使用α2 N 3亚基钙通道调节剂或与α2-δ钙通道亚基相互作用的其它化合物与一种或多种具有平滑肌的化合物组合的方法 治疗和/或减轻与正常和脊髓损伤患者的疼痛和非痛苦的下尿路疾病相关的症状的调节作用。 根据本发明，α2 N亚基钙通道调节剂包括GABA类似物（例如加巴喷丁和普瑞巴林），加巴喷丁的稠合双环或三环氨基酸类似物和氨基酸化合物。 具有平滑肌调节作用的化合物包括抗毒蕈碱，β3肾上腺素能激动剂，解痉药，神经激肽受体拮抗剂，缓激肽受体拮抗剂和一氧化氮供体。

公开(公告)号：US20110269792A1

公开(公告)日：2011-11-03

申请号：US13180113

申请日：2011-07-11

申请人： Steven B. Landau ,  Suhail Nurbhai

发明人： Steven B. Landau ,  Suhail Nurbhai

IPC分类号： A61K31/439 ,  A61P1/00

CPC分类号： A61K31/4743

摘要： The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof.

摘要翻译： 本发明涉及在需要治疗的受试者中治疗肠易激综合征（IBS-c）或肠易激综合征交替便秘和腹泻（IBS-a）的方法。 该方法包括向所述受试者施用治疗有效量的结构式I的噻吩并[3,2-b]吡啶化合物或其药学上可接受的盐或N-氧化物衍生物。

公开(公告)号：US20100152231A1

公开(公告)日：2010-06-17

申请号：US12635498

申请日：2009-12-10

申请人： Steven B. Landau ,  Suhail Nurbhai

发明人： Steven B. Landau ,  Suhail Nurbhai

IPC分类号： A61K31/439 ,  A61P1/00

CPC分类号： A61K31/4743

摘要： The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof.

摘要翻译： 本发明涉及在需要治疗的受试者中治疗肠易激综合征（IBS-c）或肠易激综合征交替便秘和腹泻（IBS-a）的方法。 该方法包括向所述受试者施用治疗有效量的结构式I的噻吩并[3,2-b]吡啶化合物或其药学上可接受的盐或N-氧化物衍生物。

公开(公告)号：US20080269276A1

公开(公告)日：2008-10-30

申请号：US12069439

申请日：2008-02-08

申请人： Steven B. Landau ,  Suhail Nurbhai

发明人： Steven B. Landau ,  Suhail Nurbhai

IPC分类号： A61K31/439 ,  A61P1/00

CPC分类号： A61K31/4743

摘要： The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof.

摘要翻译： 本发明涉及在需要治疗的受试者中治疗肠易激综合征（IBS-c）或肠易激综合征交替便秘和腹泻（IBS-a）的方法。 该方法包括向所述受试者施用治疗有效量的结构式I的噻吩并[3,2-b]吡啶化合物或其药学上可接受的盐或N-氧化物衍生物。